Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of <scp>CYP2C19</scp> genetic variation and obesity in the pediatric populationElizabeth J. Thompson, Daniel González, Angela Jeong et al.|CPT Pharmacometrics & Systems Pharmacology|2024Cited by 5
Using Real‐World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and InfantsSean McCann, Daniel González, Chi D. Hornik et al.|The Journal of Clinical Pharmacology|2024Cited by 3
Characterizing Enoxaparin’s Population Pharmacokinetics to Guide Dose Individualization in the Pediatric PopulationFernando Carreño, Jacqueline G. Gerhart, Victória Etges Helfer et al.|Clinical Pharmacokinetics|2024Cited by 3
Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World DataSean McCann, Daniel González, Victória Etges Helfer et al.|Clinical and Translational Science|2025Cited by 3
Evaluation of Obesity‐Related Physiological Changes on Pantoprazole Clearance in Children Using a Population Pharmacokinetic ApproachTyler Dunlap, Valentina Shakhnovich, Daniel González et al.|The Journal of Clinical Pharmacology|2024Cited by 1